XM does not provide services to residents of the United States of America.
F
F

Fidelity

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

S&P 500 top and bottom performing stocks at about 03:30 p.m. EDT

BUZZ - S&P 500 top and bottom performing stocks at about 03:30 p.m. EDT S&P 500 .SPX Top Performers Percent Change NVIDIA Corp NVDA.OQ +7.0% Ralph Lauren Corp RL.N +4.1% Vistra Corp VST.N +3.7% Freeport-McMoRan Inc FCX.N +3.6% DaVita Inc DVA.N +3.5% Bottom Performers Percent Change Moderna Inc MRNA.OQ -8.8% Builders FirstSource Inc BLDR.N -5.3% Mar
N
U
F
D
M
P

U.S. STOCKS Henry Schein, Dave, Delek

BUZZ-U.S. STOCKS ON THE MOVE-Henry Schein, Dave, Delek Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. stock indexes rose on Tuesday, extending their recent run on expectations that the Federal Reserve will cut interest rates this year, while a drop in Walt Disney shares following quarterly results limited overall market gains.
A
B
T
U
U
F
L
A
F
H
I

U.S. STOCKS Vanda Pharmaceuticals, FMC, Duke Energy

BUZZ-U.S. STOCKS ON THE MOVE-Vanda Pharmaceuticals, FMC, Duke Energy Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. stock indexes rose on Tuesday, extending their recent run on expectations that the Federal Reserve will cut interest rates this year, while a drop in shares of Walt Disney following the company's quarterly results limited their gains.
A
B
N
T
U
U
F
A
F
H
I
J

FIS climbs after raising 2024 profit forecast above Street estimates

BUZZ-FIS climbs after raising 2024 profit forecast above Street estimates ** Shares of banking and payments processing conglomerate Fidelity National Information Services FIS.N rise ~4.7% to $73.79 ** FIS after market on Monday said it now expects annual adjusted EPS between $4.88 and $4.98, higher than its previous forecast of $4.66 to $4.76 ** An
U
F

U.S. Perficient, Target, Vertex Pharmaceuticals

U.S. RESEARCH ROUNDUP- Perficient, Target, Vertex Pharmaceuticals May 7 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Perficient, Target and Vertex Pharmaceuticals, on Tuesday. HIGHLIGHTS * Cerence Inc CRNC.O : Needham cuts to hold from buy * Gap Inc GPS.N : Citigroup raises to buy from neutral * Perficient Inc PRFT.O : Alliance Global Partners cuts to neutral from buy * Target Corp TGT.N : Citigroup raises to buy
A
C
V
M
F
I
S
H
P

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.